MX2018000267A - Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. - Google Patents

Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.

Info

Publication number
MX2018000267A
MX2018000267A MX2018000267A MX2018000267A MX2018000267A MX 2018000267 A MX2018000267 A MX 2018000267A MX 2018000267 A MX2018000267 A MX 2018000267A MX 2018000267 A MX2018000267 A MX 2018000267A MX 2018000267 A MX2018000267 A MX 2018000267A
Authority
MX
Mexico
Prior art keywords
treatment
antibody
combination
cancer
hdac inhibitor
Prior art date
Application number
MX2018000267A
Other languages
English (en)
Inventor
Goodenow Robert
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2018000267A publication Critical patent/MX2018000267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

En este documento, se describen métodos para el tratamiento del cáncer de mama en un sujeto; en particular, se proporcionan métodos para el tratamiento del cáncer de mama metastásico triple negativo con una combinación de entinostat y un anticuerpo anti-PD-L1, tal como MPDL3280A.
MX2018000267A 2015-06-29 2016-06-28 Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. MX2018000267A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186237P 2015-06-29 2015-06-29
PCT/US2016/039906 WO2017004092A1 (en) 2015-06-29 2016-06-28 Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018000267A true MX2018000267A (es) 2018-05-22

Family

ID=57609540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000267A MX2018000267A (es) 2015-06-29 2016-06-28 Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.

Country Status (13)

Country Link
US (1) US20180353602A1 (es)
EP (1) EP3313433A4 (es)
JP (1) JP2018519335A (es)
KR (1) KR20180022926A (es)
CN (1) CN107921108A (es)
AU (1) AU2016285597A1 (es)
BR (1) BR112017028287A2 (es)
CA (1) CA2990687A1 (es)
HK (1) HK1255916A1 (es)
IL (1) IL256439A (es)
MX (1) MX2018000267A (es)
RU (1) RU2018103064A (es)
WO (1) WO2017004092A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166986A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3270966B1 (en) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine.
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
JP2018538321A (ja) * 2015-12-28 2018-12-27 シンダックス ファーマシューティカルズ，インコーポレイティド 卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
EP3400009A2 (en) * 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019530704A (ja) * 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド がんの処置のためのアベルマブの投与レジメン
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
US11090286B2 (en) * 2018-06-15 2021-08-17 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
CA3111809A1 (en) * 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
JP7457330B2 (ja) 2018-12-07 2024-03-28 小野薬品工業株式会社 免疫抑制剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179738A1 (en) * 2013-05-03 2014-11-06 Syndax Pharmaceuticals, Inc. Methods for the treatment of cancer
WO2014194280A2 (en) * 2013-05-30 2014-12-04 The Board of Regents of the Nevada System of Higher Education on behalf of the University of Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells

Also Published As

Publication number Publication date
EP3313433A4 (en) 2019-01-02
CA2990687A1 (en) 2017-01-05
HK1255916A1 (zh) 2019-09-06
CN107921108A (zh) 2018-04-17
EP3313433A1 (en) 2018-05-02
KR20180022926A (ko) 2018-03-06
AU2016285597A1 (en) 2018-01-18
RU2018103064A (ru) 2019-07-30
IL256439A (en) 2018-02-28
JP2018519335A (ja) 2018-07-19
BR112017028287A2 (pt) 2018-09-04
WO2017004092A1 (en) 2017-01-05
US20180353602A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501763A1 (en) Multispecific antibodies
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
GEP20217331B (en) Anti-tigit antibodies
SG10201810108PA (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
MY176285A (en) Anti-fcrh5 antibodies
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
UA123212U (uk) Спосіб лікування раку молочної залози
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.